一分钟看懂
这是一项关于乳腺癌的II 期研究,登记的药物或干预包括Biospecimen Collection;Bone Scan;Computed Tomography;F-18 16 Alpha-Fluoroestradiol;Positron Emission Tomography;Questionnaire Administration,当前状态为招募中。登记地点显示中国Duarte、Irvine有研究中心记录。是否仍有名额以及是否值得进一步询问,需要向研究中心确认。
药物或干预
Biospecimen Collection;Bone Scan;Computed Tomography;F-18 16 Alpha-Fluoroestradiol;Positron Emission Tomography;Questionnaire Administration;Stereotactic Body Radiation Therapy · II 期
登记条件中文摘要
年龄范围:18岁及以上
登记的基本范围为不限性别,年龄18岁及以上;以下仅摘录8项专业入选条件,需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件,具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息,不代表此刻仍有名额;请向研究中心确认最新情况。
- City of Hope Medical Center · Duarte
- City of Hope at Irvine Lennar · Irvine
入选条件原文摘录
以下为摘录,请打开原始登记查看完整入排标准。
- * Documented informed consent of the participant and/or legally authorized representative
- * Age: ≥ 18 years
- * Female or male
- * Eastern Cooperative Oncology Group (ECOG) ≤ 2
- * Ability to read and understand English or Spanish for questionnaires
- * Histologically confirmed ER+ (any progesterone receptor \[PR\] and human epidermal growth factor receptor 2 \[HER2\] status is allowed) metastatic breast cancer
- * The presence of metastatic breast cancer at the time of study entry with progression in 1-4 lesions (including new lesions). Patients that have disease progression in the breast and/or ipsilateral axilla will be considered to have only 1 site of progression even if multiple nodules/lymph nodes are present. Patients with progression in \> 4 lesions are not allowed. Patients with current progression of malignant pleural effusions, malignant ascites, abdominal carcinomatosis, and/or lymphangitic pulmonary involvement are considered to have \> 4 metastases (Note that patients with a history of these conditions earlier in the disease course with no evidence of progression of these conditions are eligible.)
- * Evidence of extracranial disease progression in 1-4 discrete lesions will be defined by either of the following:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号:NCT06260033;登记信息更新于 2026-10-07;本站同步于 2026-10-08。